# Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

> **NCT02914262** · PHASE1 · COMPLETED · sponsor: **Aerpio Therapeutics** · enrollment: 40 (actual)

## Conditions studied

- IBD

## Interventions

- **DRUG:** AKB-4924
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02914262
- **Lead sponsor:** Aerpio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2016-11
- **Final completion:** 2017-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914262, "Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02914262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*